Drug Database
Back to search

Switzerland· 70733006

Ruxolitinib Sandoz 15 mg, Tabletten

A ruxolitinib product containing ruxolitinibum, registered in Switzerland by Sandoz Pharmaceuticals AG and dispensed under Swissmedic category A. The same ATC class is registered in 14 of our 19 countries.

Cat A (Swissmedic)ATC L01EJ01

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedRuxolitinib Sandoz 15 mg, TablettenATCL01EJ01REGISTER NO.70733006PACKS LISTED0CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ruxolitinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ruxolitinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EJ01 (ruxolitinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose
Search ruxolitinib products by name

Ruxolitinib · ATC L01EJ01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ruxolitinib costs, country by country.

Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.

  • Switzerland: $223.34 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ruxolitinib · price per daily dose (30 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$223.34
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
ruxolitinibum
Manufacturer
Sandoz Pharmaceuticals AG
Country
Switzerland (CH)
ATC code
L01EJ01
ATC class
Ruxolitinib
Defined daily dose
30 mg, O
Swissmedic category
A
Reimbursed
No
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

350 interactions on record for ruxolitinib.

Graded by severity as the source publishes them — 92 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ruxolitinib against other medicinesHow interaction checks work

Ruxolitinib · interactions on record

350 records

  • 92 severe
  • 199 moderate
  • 59 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • DanaparoidB01AB09severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ruxolitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ruxolitinib products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Polink, Ruxib
  • Bulgaria · Руджави, Руксолитиниб Сандоз
  • Cyprus · Ruxolitinib Sandoz
  • Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
  • Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
  • Estonia · Ruxolitinib Msn
  • Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
  • Finland · Ruxolitinib Orion
  • France · Ruxolitinib Biogaran, Ruxolitinib Olpha
  • United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
  • Greece · Jakulya
  • Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
  • Hungary · Ruxolitinib Sandoz
  • Iceland · Jakavi, Jakulya
  • Italy · Ruxolitinib Vivanta
  • Liechtenstein · Jakavi, Opzelura
  • Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
  • Latvia · Ruxolitinib Msn
  • Malta · Donlize, Ruxolitinib Medichem
  • Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
  • Norway · Jakavi, Opzelura
  • Romania · Ruxolitinib Msn
  • Sweden · Ruxolitinib Devatis, Ruxolitinib Orion

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee0a5cc9-0e09-4d1b-8812-ad010faef3d1
GET /v1/drugs/ee0a5cc9-0e09-4d1b-8812-ad010faef3d1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{}
API referenceMCP serverPlans

See everything about ruxolitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console